NGM presented data showing that its once-monthly nonalcoholic steatohepatitis drug improved insulin sensitivity in people with diabetes.
The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex.
One of Bristol-Myers Squib's key executives has now jumped ship to a small British biotech.
The expansion is driven by midphase Type 2 diabetes data suggesting tirzepatide improves markers associated with nonalcoholic steatohepatitis.
Looking to broaden its use of artificial intelligence, Johnson & Johnson’s biotech unit Janssen has penned a new deal with AI specialist nference.
Refuge is working on “intelligent” T cell therapies that can “think for themselves and react to their environment."
Understanding aging in cells beyond the brain could lead to new therapies for diabetes and more, Salk scientists say.
Halozyme CEO Helen Torley discusses the company’s two-pronged strategy, what’s up next for the company and why biotechs are filing IPOs earlier.
Bristol-Myers unveils R&D team for after Celgene deal; GE Healthcare exec to lead LEO Pharma; and after 31 years at Merck, Schechter jumps to LabCorp.
The outlay will give Vertex owenership of Exonics and expand its deal with CRISPR, setting it up to use gene editing to treat DMD and DM1.